<h4>Background</h4>The implementation gap between evidence-based SGLT2 inhibitor therapy and real-world practice remains substantial in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.